Sanofi’s move for Dren Bio’s clinical asset boosts its immunology-focused strategy of becoming a leader in the field.

In the latest move to cement its “immunology powerhouse” status, Sanofi is handing ove | The CD20-directed antibody, dubbed ...

Dr. Sara M. Tolaney discussed HER2-positive breast cancer, highlighting key trials, evolving treatment strategies, and the ...

When Maria Branyas Morera died in August 2024 at the age of 117, she left behind more than just a legacy as the world’s ...

Under the terms of the deal, Sanofi will pay $600 million upfront to buy an affiliate of the California-based biotech, called ...

Elevation Oncology discontinues EO-3021 for gastric and gastroesophageal junction cancers after phase 1 trial shows ...

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer ...

Accelerated aging in breast cancer survivors is linked to treatments and tumor characteristics, with implications for ...

ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies, announces its participation in the 2025 NeauxCancer Conference organized by the Cancer Advocacy ...

Chugai introduces Lunsumio for intravenous infusion, a bispecific antibody to treat relapsed or refractory follicular lymphoma in Japan: Tokyo Thursday, March 20, 2025, 11:00 Hrs ...

研究人员采用了病例对照研究的方法，选取了 90 名在开罗大学国家癌症研究所确诊的 BC 女性患者，并以 30 名年龄和性别相匹配的健康个体作为对照。在患者接受可能影响基因表达的治疗之前，采集他们的外周血样本，同时收集对照个体的外周血样本。

HighTower Advisors LLC raised its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA – Free Report) by 32.3% in ...